Table 2.
Characteristics of studies included in meta-analysis.
| Author/year | Age | Anticoagulant used | Patients, total | Patients, FVL mutation | Patients with unprovoked VTE | Observation period | Recurrences, total | Recurrences, FVL mutation |
|---|---|---|---|---|---|---|---|---|
| Years (mean or median) | Numbers | Numbers | Numbers | Months (mean/median) | Numbers (%) | Numbers (%) | ||
| Simioni et al. (67)+ (provoked VTE) | 63 | VKA | 106 | 13 | 0 | 47 | 10 (9.4) | 4 (30.1) |
| Simioni et al. (67)+ (unprovoked VTE) | 63 | VKA | 145 | 28 | 145 | 47 | 39 (26.9) | 10 (35.7) |
| Kearon et al. (69)# (placebo group) | 58 | VKA | 83 | 19 | 83 | 9 | 17 (20.5) | 2 (10.5) |
| Kearon et al. (69)# (intervention group) | 59 | VKA | 79 | 15 | 79 | 12 | 1 (1.7) | 0 (0.0) |
| Lindmarker et al. (64) | 58 | VKA | 467 | 118 | 267 | 48 | 65 (13.9) | 19 (16.1) |
| Miles et al. (63) | 40–84$ | – | 218 | 26 | 101 | 88 | 29 (13.3) | 5 (19.2) |
| Palareti et al. (75) | 67 | VKA | 599 | 68 | 282 | 17 | 58 (9.7) | 15 (22.1) |
| Christiansen et al. (65) | 45 | VKA | 474 | 84 | 259 | 88 | 90 (19) | 19 (22.6) |
| Vossen et al. (70) | 40 | – | 304 | 76 | 167 | 67 | 51 (16.8) | 12 (15.8) |
| Wahlander et al. (17)# (placebo group) | 58 | VKA | 531 | 121 | – | 18 | 57 (10.7) | 16 (13.2) |
| Wahlander et al. (17)# (intervention group) | 56 | DOAC | 549 | 100 | – | 18 | 9 (1.6) | 2 (2) |
| Gonzalez-Porras et al. (46) | 47 | VKA | 181 | 29 | 117 | 56 | 27 (14.9) | 5 (17.2) |
| Prandoni et al. (78) | 66 | VKA | 953 | 111 | – | 50 | 208 (21.8) | 38 (34.2) |
| Poli et al. (82) | 64 | VKA | 169 | 22 | 107 | 30 | 27 (15.9) | 5 (22.7) |
| Eichinger et al. (86) | 49 | VKA | 1,107 | 307 | 1,107 | 44 | 168 (15.2) | 60 (19.5) |
| Rodger et al. (84) | 53 | VKA | 646 | 100 | 646 | 18 | 91 (14.1) | 19 (19) |
| Kearon et al. (73) | 57 | VKA | 661 | 161 | 661 | 28 | 14 (2.1) | 3 (1.9) |
| Chaireti et al. (71) | 61 | VKA | 158 | 39 | – | 84 | 42 (26.5) | 17 (43.6) |
| Obeidat et al. (83) | 50 | – | 72 | 17 | 23 | 6 | 7 (9.7) | 2 (11.8) |
| Sveinsdottir et al. (37) | 63 | VKA | 1,267 | 339 | 511 | 58 | 131 (10.3) | 49 (14.5) |
| Olie et al. (36) | 49 | VKA | 583 | 49 | 583 | 27 | 74 (12.6) | 9 (18.4) |
| Weingarz et al. (38) | 43 | – | 1,221 | 287 | 299 | 77 | 261 (21.4) | 63 (22) |
| Franco Moreno et al. (103) | 61 | VKA | 398 | 106 | 398 | 21 | 65 (16.3) | 45 (42.5) |
| Bruzelius et al. (39) | 46 | – | 1,010 | 238 | 367 | 60 | 101 (10) | 33 (13.9) |
| Mean et al. (48) | 76 | VKA | 354 | 32 | 354 | 30 | 54 (15.3) | 4 (12.5) |
| Limperger et al. (40) | 37 | – | 1,012 | 275 | 223 | 51 | 178 (17.6) | 68 (24.7) |
| Hodeib et al. (41) | 52 | VKA | 224 | 60 | 224 | 50 | 58 (25.9) | 22 (36.7) |
+
Provoked and unprovoked VTE patients were reported separately;
#
intervention and placebo group of a randomized controlled trial were reported separately; –data not reported;
$
range.